Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of lupus (sle).

Vitamin D modulates the immune response and blocks induction of an interferon (IFN) signature by systemic lupus erythematosus (SLE) sera.

This study was undertaken to investigate the effects of vitamin D supplementation on the IFN signature in patients with SLE.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Disease activity, adverse events, and endocrine effects were assessed.

What Was Measured

The subject headings attached to it are Adaptor Proteins, Signal Transducing, Antibodies, Anti-Idiotypic, Antigens, Carrier Proteins, Cholecalciferol, Cytoskeletal Proteins and DNA.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with lupus (sle).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Arthritis & rheumatology (Hoboken, N.J.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Lupus (SLE) research.